Weerasak Nawarawong

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 132 citations

Hematological Malignancy, Frontline Bortezomib, Lymphoid Neoplasia +13

Clinical profiles of multiple myeloma in Asia—An Asian Myeloma Network study

Jae Hoon Lee, Jin Seok Kim, Chang Ki Min et al. · American Journal of Hematology · 2014 · 122 citations · Full text

Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial

Ulrich Jaeger, Marek Trněný, Helen Melzer et al. · Haematologica · 2015 · 83 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Rituximab Maintenance Therapy +14

Non‐Hodgkin lymphoma in South East Asia: An analysis of the histopathology, clinical features, and survival from Thailand

Tanin Intragumtornchai, Udomsak Bunworasate, Kitsada Wudhikarn et al. · Hematological Oncology · 2017 · 46 citations

Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries

Vânia Hungria, Jae Hoon Lee, Ângelo Maiolino et al. · Annals of Hematology · 2019 · 27 citations · Full text

Hematological Malignancy, Epidemiology, Medicine +11